Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Artificial heart research

This article was originally published in The Gray Sheet

Executive Summary

National Heart, Lung, and Blood Institute awards three contracts for development of a total artificial heart and for evaluation of its compatibility with body tissues. Three teams -- Abiomed and the Texas Heart Institute; Nimbus, Inc. and the Cleveland Clinic Foundation; and Pennsylvania State University and Sarns/3M Health Care -- will each receive between $5 mil. and $6 mil. over a three-year Phase I period. The University of Utah, one of the NHLBI developers until now ("The Gray Sheet, May 25, 1992, I&W-8), did not receive additional funding. NHLBI says the two most promising artificial hearts will be selected to proceed to Phase II, for which funding would range between $8 mil. and $9 mil. over four years.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT001248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel